Navigation Links
SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference

DUBLIN, Calif., July 06, 2007 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that Dr. Gregory Berk, Chief Medical Officer, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Thursday, July 12, 2007 at the Mandarin Oriental Hotel in New York City.

SuperGen's presentation at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference is scheduled to begin at 3:30 p.m. EDT. A live webcast of the presentation will be available on the Investor Relations section of the Company's Web site at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

    Contacts:

    SuperGen                                SuperGen

    Timothy L. Enns                         Mary M. Vegh

    S.V.P., Corporate Communications        Manager, Investor Relations

    & Business Development                  (925) 560-2845

    (925) 560-0100 x111                     

    

mary.vegh@supergen.com tenns@supergen.com

CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment, +1-925-560-0100, Ext. 111, , or Mary M.Vegh, Manager, Investor Relations, +1-925-560-2845, ,both of SuperGen tenns@supergen .com mary.vegh@supergen.com

Web site: http://www.supergen.com/

Ticker Symbol: (NASDAQ-NMS:SUPG)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
2. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... HARRISBURG, Pa. , Jan. 17, 2017 ... Drug and Alcohol Programs Secretary Gary Tennis ... with carfentanil, following two recent overdose deaths from the ... "Carfentanil is intended to sedate large animals ... potentially kill anyone who comes into contact with it," ...
(Date:1/17/2017)... 2017 EU5 Glucose Monitoring Market Outlook to ... Glucose Monitoring Market Outlook to 2022", provides key market ... provides value, in millions of US dollars, volume (in ... Blood Glucose Meters, Blood Glucose Test Strips and Lancets. ... shares data for each of these market segements, and ...
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... USD 8.02 billion by 2021 from USD 6.35 billion ... major factors driving the growth of this market are ... increasing demand for minimally invasive surgeries. The ... type, procedure, application, and region. On the basis of ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland ... collaborating on a research project focused on multiple sclerosis (MS). Led by Christopher ... nanotechnology to control the disease without compromising normal immune function that often occurs ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... pleased to announce that their Vice President of Franchise Development, Paula Turner Pizarro, ... This award-winning business program, which features the insights of top business leaders from ...
(Date:1/18/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent Biologics ... at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, 2017. , ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... ... 2017 , ... For breast cancer clinicians and researchers who were unable to ... more intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th ... Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, ...
Breaking Medicine News(10 mins):